Active Ingredient History
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). There is some evidence it may improve some ME/CFS symptoms. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 2)
DNA Mismatch Repair (Phase 2)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Fatigue Syndrome, Chronic (Phase 3)
Hamartoma (Phase 1/Phase 2)
HIV Infections (Phase 2)
HIV Seropositivity (Phase 2)
HLA-A2 Antigen (Phase 2)
Influenza, Human (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 1/Phase 2)
Microsatellite Instability (Phase 2)
Neoplasm Metastasis (Early Phase 1)
Neoplasms (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 1/Phase 2)
Post-Acute COVID-19 Syndrome (Phase 2)
Prostatic Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue